Results 31 to 40 of about 384,231 (258)
Biomedicines, 2022 Monoclonal antibody (mAb) therapy has opened a new era in the pharmaceutical field, finding application in various areas of research, from cancer to infectious diseases.
Fabiola Vacca +2 more
doaj +1 more source
Discovery of a new class of integrin antibodies for fibrosis [PDF]
Scientific Reports, 2020 Abstract Lung fibrosis, or the scarring of the lung, is a devastating disease with huge unmet medical need. There are limited treatment options and its prognosis is worse than most types of cancer. We previously discovered that MK-0429 is an equipotent pan-inhibitor of αv integrins that reduces proteinuria and kidney fibrosis in a ...
Ji Zhang +27 more
openaire +4 more sources
Molecular Therapy: Methods & Clinical Development, 2020 The recombinant adeno-associated virus (AAV) vector is one of the most utilized viral vectors in gene therapy due to its robust, long-term in vivo transgene expression and low toxicity.
James H. Kurasawa +9 more
doaj +1 more source
Discovery of an antibody for pan-ebolavirus therapy [PDF]
Scientific Reports, 2016 AbstractDuring the latest outbreak of Ebola virus disease in West Africa, monoclonal antibody therapy (e.g., ZMapp) was utilized to treat patients. However, due to the antigenic differences among the five ebolavirus species, the current therapeutic monoclonal antibodies are only effective against viruses of the species Zaire ebolavirus.
Furuyama, Wakako +10 more
openaire +3 more sources
Structural and functional characterization of a DARPin which inhibits Ras nucleotide exchange
Nature Communications, 2017 Ras is mutated in many cancers, but so far no drug targeting Ras is in clinical use despite great efforts. Here the authors structurally and functionally characterize a DARPin that potently inhibits the nucleotide exchange of Ras, which might facilitate ...
Sandrine Guillard +14 more
doaj +1 more source
mAbs, 2023 Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is a critical inhibitory checkpoint molecule, and monoclonal antibodies (mAbs) targeting CTLA-4 that restore anti-tumor T cell immunity have achieved clinical success.
Jiawei Guan +16 more
doaj +1 more source
Function-first antibody discovery [PDF]
OncoImmunology, 2013 Therapeutic antibodies may mediate antineoplastic effects by altering the biological functions of their target, by directly stimulating the demise of cancer cells or by activating antibody-dependent immune effector mechanisms. We have recently provided in vivo proof-of-concept for a "function-first" target and drug discovery platform in which ...
openaire +2 more sources
Data mining patented antibody sequences
mAbs, 2021 The patent literature should reflect the past 30 years of engineering efforts directed toward developing monoclonal antibody therapeutics. Such information is potentially valuable for rational antibody design. Patents, however, are designed not to convey
Konrad Krawczyk +2 more
doaj +1 more source
Pyrrolobenzodiazepine Antibody-Drug Conjugates Designed for Stable Thiol Conjugation
Antibodies, 2017 Thiosuccinimide-linked antibody-drug conjugates (ADCs) are susceptible to drug loss over time due to a retro-Michael reaction, which can be prevented by selecting stable conjugation positions or hydrolysis of the thiosuccinimide.
R. James Christie +13 more
doaj +1 more source
mAbsCamelid-derived single domain antibodies (sdAbs), referred to as VHHs (variable domains of the heavy chain of a heavy chain-only antibodies), recently emerged as promising building blocks for the construction of therapeutic molecules. As of October 2025,
Andreas Evers +3 more
doaj +1 more source